TETON-2 Supports Antifibrotic Benefit of Inhaled Treprostinil in IPF, With Steven Nathan, MD

Inhaled treprostinil (Tyvaso; United Therapeutics) significantly preserved lung function and reduced the risk of clinical worsening compared with placebo over 52 weeks in patients with idiopathic pulmonary fibrosis (IPF) — findings that Steven D. Nathan, MD, FCCP, argues position the drug as a first inhaled antifibrotic therapy and validate a years-long hypothesis derived from an earlier pulmonary hypertension trial.

Nathan, medical director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital in Falls Church, Virginia, and chair of the TETON steering committee, was the presenting author of the TETON-2 results at the European Respiratory Society meeting in Amsterdam in September 2025., and later the full paper published in the 

spoke with Nathan to learn more about TETON-2, a phase 3, multicenter, randomized, double-blind, placebo-controlled trial enrolling 593 patients with IPF across sites in Asia-Pacific, Europe, and Latin America. Patients in the trial were randomly assigned 1:1 to receive nebulized treprostinil or placebo, titrated from 3 breaths 4 times daily to a target regimen of 12 breaths 4 times daily over 52 weeks. The mean patient age was 71.7 years, 80.1% were men, mean baseline forced vital capacity (FVC) was 76.8% predicted, and 75.4% were receiving background antifibrotic therapy with nintedanib or pirfenidone.

The trial met its primary endpoint: the median change in absolute FVC at week 52 was −49.9 mL (95% CI, −79.2 to −19.5) in the treprostinil group versus −136.4 mL (95% CI, −172.5 to −104.0) in the placebo group, yielding a between-group difference of 95.6 mL (95% CI, 52.2 to 139.0; 

 <.001). Treprostinil also significantly reduced the risk of clinical worsening, with events occurring in 81 patients (27.2%) in the treprostinil group versus 115 (39.0%) in the placebo group (hazard ratio, 0.71; 95% CI, 0.53 to 0.95; 

 = .02), a 29% risk reduction. These benefits were observed across all analyzed subgroups, including patients with and without background antifibrotic therapy, across smoking histories, and in those using supplemental oxygen. No substantial between-group difference in time to acute IPF exacerbation was observed, precluding formal inference on subsequent prespecified secondary endpoints per the hierarchical testing procedure. The most common adverse event was cough, reported in 48.3% of treprostinil-treated patients versus 24.1% of those receiving placebo; the overall safety profile was consistent with prior Tyvaso experience and known prostacyclin-related adverse events, with no new safety signals identified.

Nathan described the conceptual underpinning of the TETON program as originating from an ad hoc analysis of the INCREASE trial — a phase 3 study of inhaled treprostinil in pulmonary hypertension associated with interstitial lung disease (PH-ILD), published in the 

 in March 2021, which supported the drug's approval for that indication. Although FVC was assessed in INCREASE as a safety measure rather than an efficacy endpoint, patients who received inhaled treprostinil demonstrated better lung function at week 16 than those on placebo, and patients who crossed over to open-label treprostinil from placebo showed subsequent FVC gains — a signal Nathan characterized as suggesting independent antifibrotic properties beyond vasodilation. That hypothesis became the foundation for the TETON program, which also includes a third study, TETON-PPF, evaluating inhaled treprostinil in progressive pulmonary fibrosis beyond IPF.

TETON-1, the North American sister study enrolling 598 patients in the United States and Canada, reported positive topline results in March 2026, with treprostinil demonstrating superiority over placebo for absolute FVC change from baseline to week 52 by 130.1 mL (Hodges-Lehmann estimate, 95% CI, 82.2 to 178.1 mL; 

 <.0001) — a treatment effect exceeding that observed in TETON-2. TETON-1 also achieved statistical significance for reducing the risk of clinical worsening. United Therapeutics plans to submit a supplemental New Drug Application to the FDA by the end of summer 2026 seeking to add IPF to the labeled indications for nebulized Tyvaso, with integrated analyses of both TETON studies to be presented at the American Thoracic Society Annual Meeting in Orlando in May 2026.

“In fact, when the placebo arm got converted to open label with treprostinil, the FVCs went up. So this gave us some kind of indication that maybe treprostinil had independent anti fibrotic properties, and that was the foundation and underpinning for the TETON program,” Nathan said.

Nathan’s reported disclosures include AstraZeneca, Avalyn Pharma, Boehringer Ingelheim, Pliant, and United Therapeutics.

Nathan SD, Smith P, Deng C, et al; TETON-2 Trial Investigators. Inhaled treprostinil for idiopathic pulmonary fibrosis. 

. Published online March 11, 2026. doi:10.1056/NEJMoa2512911

United Therapeutics Corporation. United Therapeutics Corporation announces TETON-1 pivotal study of Tyvaso® meets primary endpoint for treatment of idiopathic pulmonary fibrosis, exceeding impressive treatment effect seen in TETON-2. Press release. March 30, 2026. Accessed April 10, 2026. 

https://ir.unither.com/press-releases/2026/03-30-2026-120037465

Videos

Treprostinil significantly slowed FVC decline and reduced clinical worsening events over 52 weeks in patients with IPF.


News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Pulmonary Fibrosis

Eingun James Song, MD, is the director of clinical research for Frontier Dermatology. 

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

In this episode, ‘Redefining Treatment Success in Psoriasis,’ the expert dermatologists explore the remarkable evolution of treatment expectations in psoriasis, moving from modest improvements to ambitious goals of complete skin clearance and sustained remission. The faculty reflect that in earlier treatment paradigms even a 50% improvement in disease severity was considered a meaningful success. 

Redefining Treatment Success in Psoriasis

In this episode, ‘Redefining Treatment Success in Psoriasis,’ the expert dermatologists explorethe remarkable evolution of treatment expectations in psoriasis, moving from modest improvements to ambitious goals of complete skin clearance and sustained remission. The faculty reflect that in earlier treatment paradigms even a 50% improvement in disease severity was considered a meaningful success.

As advances in immunology and targeted biologic therapies have transformed the treatment landscape, expectations have shifted dramatically. Clinicians now have a deeper understanding of the underlying inflammatory pathways driving psoriasis, enabling the development of therapies that can deliver high levels of skin clearance with improved safety profiles. As a result, conversations with patients have evolved, with many now expecting near-complete or complete resolution of their disease.

The panelists also discussed the National Psoriasis Foundation consensus definition of on-treatment remission, representing an important step toward aligning clinical goals with patient-centered outcomes. The faculty examine the rationale for establishing a formal definition, emphasizing the importance of setting clear, achievable targets that reflect both clinical efficacy and quality of life. By incorporating perspectives from clinicians, patients, and other stakeholders, this definition underscores a broader shift in psoriasis care toward sustained disease control and meaningful remission. Overall, this discussion reinforces how far the field has progressed and sets the stage for applying these elevated expectations in clinical practice.

The next episode in this series, ‘Remission as a Goal in Psoriasis,’ features the panelists examining the clinical relevance of achieving and sustaining remission in psoriasis, emphasizing that ambitious treatment goals are increasingly attainable with modern therapies. It highlights the importance of maintaining disease control over time while aligning treatment strategies with patient quality of life and long-term outcomes.

Video Series

Redefining Treatment Success in Psoriasis April 2026

Welcome back to another HCP Live Peer Exchange series. In this episode titled, ‘Evolving Treatment Expectations in Psoriasis,’ the panelists discussed how treatment goals in psoriasis have evolved alongside advances in therapeutic innovation and disease understanding. The expert faculty began by reflecting on the historical limitations of traditional therapies, including topicals, phototherapy, and early systemic agents, which were often insufficient for achieving sustained disease control. In earlier eras, treatment success was defined and accepted by improvement rather than complete clearance of the skin. 

Evolving Treatment Expectations in Psoriasis

Welcome back to another HCP Live Peer Exchange series. In this episode titled, ‘Evolving Treatment Expectations in Psoriasis,’ the panelists discussed how treatment goals in psoriasis have evolved alongside advances in therapeutic innovation and disease understanding. The expert faculty began by reflecting on the historical limitations of traditional therapies, including topicals, phototherapy, and early systemic agents, which were often insufficient for achieving sustained disease control. In earlier eras, treatment success was defined and accepted by improvement rather than complete clearance of the skin.

As the conversation progresses, the panel highlighted how the advent of biologic therapies has fundamentally reshaped expectations for both clinicians and patients. With increasing insights into psoriasis pathophysiology, particularly the role of targeted cytokine pathways, modern treatments have enabled deeper and more durable responses. This has shifted the paradigm from partial improvement to ambitious goals such as near complete or complete skin clearance.

The panelists introduce the concept of drug remission as an emerging clinical objective. The faculty discussed how advances in precision medicine have not only improved efficacy but also enhanced safety profiles, allowing clinicians to pursue sustained disease control with greater confidence. The discussion emphasized how these developments have transformed patient-provider conversations, with patients now expecting high levels of clearance without significant trade-offs in safety.

In the next episode, ‘Redefining Treatment Success in Psoriasis’, panelists will highlight how treatment expectations in psoriasis have evolved from modest improvements to achieving complete clearance and sustained remission. It will also introduce the National Psoriasis Foundation definition of on-treatment remission and its implications for aligning clinical goals with patient-centered outcomes.

Clara Bohm, MD, is a nephrologist and associate professor in the Department of Internal Medicine at the University of Manitoba. 

Intradialytic Cycling Does Not Significantly Reduce Myocardial Stunning in Hemodialysis Patients

A multisite randomized trial found intradialytic exercise led to a modest, nonsignificant reduction in myocardial stunning among patients receiving hemodialysis, highlighting both the promise and limitations of exercise as a cardiovascular intervention in this population.

Clara Bohm, MD, a nephrologist and associate professor in the Department of Internal Medicine at the University of Manitoba, presented results from a multicenter, randomized 12-week trial of intradialytic cycling targeting hemodialysis-induced myocardial stunning at the World Congress of Nephrology (WCN).

Myocardial stunning is defined by transient, repeated episodes of ischemia-induced left ventricular dysfunction and is common during hemodialysis. It has been associated with increased cardiovascular morbidity and mortality. Given the substantial symptom burden and elevated cardiovascular risk faced by patients on dialysis, investigators have increasingly explored exercise as a potential therapeutic strategy.

Intradialytic exercise refers to physical activity performed during hemodialysis sessions, typically involving low- to moderate-intensity movements such as stationary cycling or resistance training, designed to improve physical function and potentially mitigate treatment-related complications.

The rationale for targeting myocardial stunning with exercise is grounded in both clinical need and biological plausibility. Exercise may address several contributing mechanisms, including underlying cardiac disease and vascular dysfunction. Additionally, aerobic exercise has been shown in the general population to induce ischemic preconditioning, in which repeated, low-level cardiac stress improves resilience to more severe ischemic events.

Despite this rationale, prior research has been limited. Many studies have been small, observational, and conducted in highly selected populations, raising concerns about generalizability. These studies have also often been cross-sectional or nonrandomized, introducing potential bias and limiting insight into long-term effects.

To address these limitations, investigators designed a multicenter randomized trial with minimal exclusion criteria to better reflect real-world patients receiving hemodialysis. Participants in the intervention arm completed 60 minutes of intradialytic exercise three times per week over a 12-week period.

At study completion, the control group demonstrated no change in the number of stunned myocardial segments from baseline. In the exercise group, investigators observed a reduction of approximately 1.3 stunned segments after 12 weeks; however, the difference did not reach statistical significance.

“We did not detect a significant effect of exercise on myocardial stunning,” Bohm said. “It’s possible the effect is still there, but smaller than what’s been seen in more selective populations.”

Importantly, the study cohort differed meaningfully from those in prior trials. The population included a higher proportion of women, approximately 20% Indigenous participants in the US, and about 35% of patients in each arm with significant heart failure—groups often underrepresented in earlier studies.

Adherence to the exercise intervention was consistent with other behavioral trials, with participants completing approximately 65% of prescribed sessions and achieving target intensity overall. However, subgroup analysis suggested disparities in engagement, particularly among women, who participated in fewer sessions, exercised for shorter durations, and at lower intensity.

“There’s a lot of enthusiasm around exercise as a therapy,” Bohm said. “But it’s critical that we test these interventions in larger, representative populations so we know what truly works.”

The study was conducted through a collaborative network of researchers focused on advancing exercise science in kidney disease, including the Global Renal Exercise Network.

Bennett PN, Penny JD, McIntyre CW, et al. Randomized Controlled Trial of Intradialytic Cycling as Kidney Exercise Rehabilitation for Cardiac Stunning in Hemodialysis (TICKERS_HD): A Clinical Research Protocol. 

Canadian journal of kidney health and disease

https://doi.org/10.1177/20543581251391112

Safoora Shahzeidi, Firouzeh Moeinzadeh, Shahidi S. Evaluating the effect of intradialytic cycling exercise on quality of life and recovery time in hemodialysis patients: A randomized clinical trial. 2022;27(1):84-84. doi:

A multicenter RCT of intradialytic cycling showed a modest, nonsignificant reduction in myocardial stunning in hemodialysis patients.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Mercedes Martinez, MD, is a professor of pediatrics and medicine, medical director of the intestinal transplant program at the Center for Liver Disease and Abdominal Organ Transplantation, and medical director of the pediatric abdominal organ transplantation program at NewYork-Presbyterian.

The Rise of IBAT Inhibitors in Cholestatic Disease Management

As the treatment landscape for rare cholestatic liver diseases evolves, focus is shifting beyond biochemical control to the broader burden of disease. With the emergence of ileal bile acid transporter (IBAT) inhibitors, clinicians are beginning to rethink traditional treatment approaches and their potential to improve both symptoms and long-term outcomes.

In 2025, maralixibat (Livmarli) was granted US Food and Drug Administration (FDA) approval for the treatment of cholestatic pruritus in patients with 

Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC)

. Most recently, the FDA approved linerixibat (Lynavoy), another IBAT inhibitor, for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC). Now, the class of agents is being explored in other rare cholestatic liver diseases in the phase 3 EXPAND trial.

Clinical trials of IBAT inhibitors have primarily focused on pruritus reduction as a primary endpoint, but Mercedes Martinez, MD, a professor of pediatrics and medicine at CUMC, pointed to growing evidence suggesting broader clinical impact. Drawing from registry data and observational cohorts, she noted that patients treated with these agents appear to experience improved native liver survival, reduced need for transplantation, and better nutritional status.

Although the precise mechanisms remain under investigation, she explained that reducing bile acid recirculation likely mitigates hepatotoxicity, while relief from severe pruritus may improve sleep, appetite, and growth.

For Martinez, however, the most striking impact is seen in quality of life. She described dramatic transformations in pediatric patients whose lives had previously been dominated by relentless itching. The downstream effects, including better sleep, improved school performance, and reduced caregiver burden, underscore how profoundly pruritus can shape daily life for both patients and families.

“These kids come to the office, and the skin is like leather [because of how] much they scratch. And now, seeing these kids coming to the office, the skin is very smooth. They are happier, they are doing better in school, because they can focus,” Martinez explained. “It just goes beyond the itch.”

This evolving understanding is also influencing her treatment approach. Traditionally, management of cholestatic pruritus has followed a stepwise paradigm, beginning with antihistamines or bile acid sequestrants and escalating to agents like rifampin. However, Martinez said she now questions that framework. Given the limited efficacy and frequent side effects of older therapies, she believes IBAT inhibitors may warrant earlier use. In her own practice, she has already begun shifting toward these agents as frontline therapy in conditions like PFIC and Alagille syndrome, tailoring dosing based on symptom severity and response.

Despite the promise, Martinez acknowledged ongoing challenges, particularly around access and cost. She stressed that studies like Mirum Pharmaceuticals’ EXPAND study of maralixibat, though limited in size, provide important proof of concept for broader application across cholestatic liver diseases.

Looking ahead, she expressed hope that regulators and payers will recognize the value of these therapies, not only in reducing symptoms, but in meaningfully improving long-term outcomes and quality of life for patients with rare liver diseases.

Editors’ Note: Martinez reports no relevant disclosures.

Brooks A. FDA Approves Maralixibat (Livmarli) Tablet for Alagille Syndrome, PFIC. HCPLive. April 14, 2025. Accessed April 10, 2026. 

https://www.hcplive.com/view/fda-approves-maralixibat-livmarli-tablet-alagille-syndrome-pfic

Brooks A. FDA Approves Linerixibat (Lynavoy) As First Treatment for Cholestatic Pruritus in PBC. HCPLive. March 19, 2026. Accessed April 10, 2026. 

https://www.hcplive.com/view/fda-approves-linerixibat-lynavoy-as-first-treatment-for-cholestatic-pruritus-in-pbc

Mirum Pharmaceuticals. Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases. March 16, 2026. Accessed April 10, 2026. 

https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Completes-Enrollment-in-Phase-3-EXPAND-Study-of-LIVMARLI-maralixibat-in-Additional-Rare-Cholestatic-Liver-Diseases/default.aspx

Martinez describes how IBAT inhibitors are reshaping cholestatic pruritus care, with impacts on symptoms, growth, and long-term liver outcomes.

Hepatology

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Optimizing Cholestatic Disease Care With IBAT Inhibitors, With Mercedes Martinez, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Articles

These new dermatology guidelines represent the first-ever atopic dermatitis-centered guidelines for pediatric patients issued by the AAD.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

First-Ever Pediatric Eczema Guidelines Issued by American Academy of Dermatology

This review of dermatology news from the first quarter of 2026 highlights key headlines, FDA news, and more.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Q1 2026 Recap: Dermatology News and Updates

Dominic Sisti, PhD, is an associate professor in the Department of Medical Ethics & Health Policy and the director of the Scattergood Program for the Applied Ethics of Behavioral Health Care. Sisti is also the host of 

, our monthly multimedia series on medical ethics in modern healthcare. 

Sisti discusses ethics, safety, and guardrails as patients use ChatGPT for mental health support and clinicians navigate AI’s role in psychiatry.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

AI in Psychiatry Raises Ethics Questions With Dominic Sisti, PhD

Aaron Troy, MD, MPH, is a clinical research fellow in cardiovascular medicine at Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center.

Troy discusses the recent changes to the ABCs of CVD, highlighting an increased focus on lifestyle interventions and the management of risk factors.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Arrhythmia

Strategic Alliance Partnership

Reviewing the Updated ABCs of Cardiovascular Disease Prevention, With Aaron Troy, MD, MPH

Simon Davies, MD, is  a consultant nephrologist at the University Hospital of North Midlands and Professor of Nephrology and Dialysis Medicine, as well as director of the Institute for Applied Clinical Sciences at Keele University.

Davies explains the future of at-home dialysis access, including policy changes and technological innovation. 

Chronic Kidney Disease

Expanding Dialysis Access: Policy, Variation, and the Role of Peritoneal Dialysis

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Experts discuss interpreting genetic testing in liver disease, the role of biopsy, and how to integrate variants into clinical decision-making.

Putting the Pieces Together: Genetic Testing, Biopsy, and Clinical Judgment

Nicole Chase, MD, is a board-certified allergist/immunologist at St. Paul Allergy Asthma, Minneapolis VA Health Care System (part-time), and an associate professor of medicine at the University of Minnesota Medical School.

Chase discusses how the FDA’s labeling change aligns epinephrine nasal spray (neffy) with other weight-based epinephrine formulations.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Weight-Based Dosing Informs Age Removal for Epinephrine Nasal Spray, With Nicole Chase, MD

Alberico Catapano, PhD, is the research director and head of the laboratory of lipoproteins and atherosclerosis and of the lipid clinic at MultiMedica IRCCS.

Catapano discusses the superior reduction in LDL-C, ApoB, and non-HDL-C demonstrated by enlicitide, suggesting its role as an add-on for LDL-C lowering.

Dyslipidemia

Enlicitide Superior to Oral Non-Statin Therapies for LDL-C Lowering, With Alberico Catapano, PhD

Robert Gish, MD, is the Medical Director of the Hepatitis B Foundation in Doylestown, Pennsylvania. He is an Adjunct Professor of Medicine at the University of Nevada School of Medicine in Las Vegas. He serves as an Adjunct Professor of Pharmacy at Skaggs School of Pharmacy and Pharmaceutical Sciences at UCSD, a Clinical Professor of Medicine at Loma Linda University. In addition, he is the Medical Director of the American Pacific Health Foundation.

In this segment of Liver Lineup, experts discuss genetic testing in cholestatic disease, highlighting real-world cases demonstrating the value of these tests.

Genetic Panels in Hepatology: Identifying the Right Patients

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Experts unpack new T2-targeted biologics for severe asthma and eosinophilic COPD, sharing biomarker tips, sequencing debates and payer hurdles,

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Latest News

TETON-2 Supports Antifibrotic Benefit of Inhaled Treprostinil in IPF, With Steven Nathan, MD

Redefining Treatment Success in Psoriasis April 2026

Evolving Treatment Expectations in Psoriasis

Intradialytic Cycling Does Not Significantly Reduce Myocardial Stunning in Hemodialysis Patients

Optimizing Cholestatic Disease Care With IBAT Inhibitors, With Mercedes Martinez, MD